Lilly is also running two other trials with eloralintide plus tirzepatide, including another mid-stage study in obese and overweight type 2 diabetes patients, with an initial completion date in June 2026, and a Phase I trial in nondiabetic individuals, scheduled to complete in October 2025
Metformin alleviates cerebral ischemia/reperfusion injury aggravated by hyperglycemia via regulating AMPK/ULK1/PINK1/Parkin pathway-mediated mitophagy and apoptosis
Cagrilintide monotherapy at 4.5 mg weekly achieved 10.8% average weight loss over 26 weeks versus 3% with placebo in its Phase 2 dose-finding trial
For a 10mg/mL solution (5mL water added), draw 0.5mL per 5mg dose
GHK-Cu + Microneedling Microneedling increases scalp blood flow and creates microchannels for deeper product penetration
Oral supplements might work for some, however, as we age, our ability to break down oral supplements often decreases